Granules India Ltd (GRANULES)

📊 Quarterly Results (₹ Cr)

Revenue growth accelerated to 22% YoY in Q1 FY27, up from 15.9% in Q3 FY25, while PAT growth outpaced revenue at 60% YoY, indicating operating leverage. EBITDA margins remain robust at 23% (up from 15.9% in Q3 FY25), supported by gross margin expansion to 65.6% (+74 bps YoY), directly tied to Complex Gx's rising contribution. Sequential revenue stability (₹14,768 crores in Q1 FY27 vs. ₹14,768 crores in prior quarter, though prior data not fully disclosed) and improving profitability metrics suggest the company is successfully scaling high-margin products, even as it navigates macro cost pressures.

🔮 Management Outlook & What's Next

Management expressed confidence in delivering sustainable growth, citing strengthened foundations, strategic clarity, and business resilience, with explicit commitments to continued investment in R&D, digitalization, and operational excellence to support long-term value creation. Forward guidance emphasizes complex product expansion and global market penetration, particularly in the US, as key growth vectors, while acknowledging external cost pressures, indicating a focus on pricing discipline and operational efficiency to protect margins.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

The balance sheet reflects a deliberate and successful deleveraging strategy, with net debt/EBITDA plummeting to 0.07x from 0.34x YoY and net debt declining to ₹1,012 crores in Q1 FY27, down from higher levels in prior quarters. Borrowings remain low and stable (~₹1,338 crores in March 2026), while equity and reserves have grown steadily, supporting a strong equity base. This financial discipline enables strategic reinvestment in R&D and operations without dilutive capital raises, reinforcing management’s focus on organic growth and capital efficiency.

💰 Cash Flow Statement (₹ Cr)

👥 Shareholding Pattern

Institutional interest is rising, with FII holdings increasing from 13.55% in Q3 FY26 to 17.5% in Q1 FY27, and DII from 17.48% to 16.11%, indicating growing confidence among foreign and domestic institutional investors. Promoter holding remains stable at 38.02%, with no signs of dilution or selling pressure. The expanding shareholder base (1,69,422 shareholders) and rising institutional participation suggest improving market perception and potential inclusion in broader indices, which could drive further liquidity and valuation re-rating.

⚖️ Peer Comparison — Pharmaceuticals

🔗 Peer Stock Analyses

⚠️ Risk Factors

1) Revenue growth showed signs of sequential slowdown (though YoY remains strong), raising concerns about sustainability amid pricing pressures in the US generic market. 2) Reliance on Complex Gx for 50% of FD revenue creates concentration risk, despite its higher margins; any regulatory or supply chain disruption could impact this segment. 3) R&D intensity at 6% of sales is elevated and may pressure near-term profitability if pipeline development faces delays or cost overruns. 4) Despite strong net debt reduction, macroeconomic headwinds from US pricing and foreign exchange volatility could impact future earnings visibility.

📋 Recent Filings

• 🔴 Announcement2026-09-29Granules India announced that the audio recording of its September 29, 2026 investor webinar is now available on its website at the provided link, off…
• 🔴 Announcement2026-09-26Granules India announced an investor webinar on September 29, 2026, at 4:30 p.m. IST to discuss its transformation strategy, including growth in contr…
• Announcement2026-09-25Granules India Ltd announced that its insider trading window will close on October 1, 2026, remaining shut until 48 hours after the unaudited Q2 resul…
• 🔴 Announcement2026-09-23Granules India announced an analyst/investor meeting scheduled for September 28, 2026 in New Delhi, noting the session is tentative and will not cover…
• 🔴 Corporate Action2026-09-16Granules India announced the allotment of 2,49,82,906 fully paid-up equity shares of Re. 1 each to promoter group members upon conversion of warrants,…
• 🔴 Corporate Action2026-09-15Granules India disclosed that promoter group members paid 75% of the Rs. 1,093 crores subscription amount for preferential convertible warrants, fully…
• 🔴 Announcement2026-09-11Granules India announced an analyst/investor meeting scheduled for September 18, 2026 in Hyderabad, inviting market participants to discuss its busine…
• Announcement2026-09-11Granules India disclosed that promoter Dr. Krishna Prasad Chigurupati sold 1.72 million shares via block deal and open market on September 11, 2026, r…
• Announcement2026-08-13Granules India announced the internal transfer of Chief Strategy Officer Sanjay Kumar to its subsidiary Ascelis Peptides, effective August 13, 2026, w…
• 🟡 Board Meeting2026-08-13No summary available

🧠 Analyst's Read

Granules India is executing a clear and disciplined transformation toward high-margin specialty generics, supported by strong financial performance, improving leverage, and rising institutional confidence. The next critical watchpoint is whether revenue growth can re-accelerate beyond current levels and how effectively the company converts its robust R&D pipeline into commercial success, particularly in the highly competitive US market, to sustain its margin expansion and valuation premium.

Based on filing content and financial data. Not a recommendation.